BG 75098
Alternative Names: BG-75098Latest Information Update: 17 Mar 2026
At a glance
- Originator BeOne Medicines
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Dec 2025 Phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Australia, China, Denmark (PO) (NCT07226349)
- 11 Dec 2025 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Australia, China, Denmark (PO) (NCT07226349)
- 14 Nov 2025 BeOne Medicine plans a phase I trial for Solid tumours (Monotherapy, Combination therapy, Late stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) in December 2025 (NCT07226349)